Bruton’s tyrosine kinase inhibition reduces disease severity in a model of secondary progressive autoimmune demyelination
Authors:
- Kirsten Scarlett EvonukKEKirsten Scarlett Evonuk
- Sen WangSWSen Wang
- Josh MattieJMJosh Mattie
- C. J. CracchioloCCC. J. Cracchiolo
- Reine MagerRMReine Mager
- Željko FerenčićŽFŽeljko Ferenčić
- Ethan SpragueESEthan Sprague
- Brandon CarrierBCBrandon Carrier
- Kai SchofieldKSKai Schofield
- Evelyn MartinezEMEvelyn Martinez
- Zachary StewartZSZachary Stewart
- Tara PetrosinoTPTara Petrosino
Open Access
- 12 July 2023
- journal article
- research article
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 11 (1) , 1-19
Abstract
Bruton’s tyrosine kinase (BTK) is an emerging target in multiple sclerosis (MS). Alongside its role in B cell receptor signaling and B cell development, BTK regulates myeloid cell activation and inflammatory responses. Here we demonstrate efficacy of BTK inhibition in a model of secondary progressive autoimmune demyelination in Biozzi mice with experimental autoimmune encephalomyelitis (EAE). We show that late in the course of disease, EAE severity could not be reduced with a potent relapse inhibitor, FTY720 (fingolimod), indicating that disease was relapse-independent. During this same phase of disease, treatment with a BTK inhibitor reduced both EAE severity and demyelination compared to vehicle treatment. Compared to vehicle treatment, late therapeutic BTK inhibition resulted in fewer spinal cord-infiltrating myeloid cells, with lower expression of CD86, pro-IL-1β, CD206, and Iba1, and higher expression of Arg1, in both tissue-resident and infiltrating myeloid cells, suggesting a less inflammatory myeloid cell milieu. These changes were accompanied by decreased spinal cord axonal damage. We show similar efficacy with two small molecule inhibitors, including a novel, highly selective, central nervous system-penetrant BTK inhibitor, GB7208. These results suggest that through lymphoid and myeloid cell regulation, BTK inhibition reduced neurodegeneration and disease progression during secondary progressive EAE.Keywords
This publication has 58 references indexed in Scilit:
- Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysisCochrane Database of Systematic Reviews, 2013
- Oligodendrocytes and the early multiple sclerosis lesionAnnals of Neurology, 2012
- Intracerebral immune complex formation induces inflammation in the brain that depends on Fc receptor interactionActa Neuropathologica, 2012
- Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)British Journal of Pharmacology, 2011
- The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cellsArthritis Research & Therapy, 2011
- Mechanism of Action of Oral Fingolimod (FTY720) in Multiple SclerosisClinical Neuropharmacology, 2010
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- Immunopathology of secondary‐progressive multiple sclerosisAnnals of Neurology, 2001
- Defective B cell development and function in Btk-deficient miceImmunity, 1995